• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

风险与暴露评估中基于生理学的药代动力学模型

Physiologically-based pharmacokinetic models in risk and exposure assessment.

作者信息

Blancato J N

机构信息

United States Environmental Protection Agency Office of Research and Development, Environmental Monitoring Systems Laboratory, Las Vegas, Nevada.

出版信息

Ann Ist Super Sanita. 1991;27(4):601-8.

PMID:1820732
Abstract

Pharmacokinetic non-linearities occur between different doses and between different species. Physiologically based pharmacokinetic models are accurate tools for taking these non-linearities into account. Dichloromethane and perchloroethylene are two examples discussed in this paper. For dichloromethane the pharmacokinetic non-linearity factor results in a greater delivered dose than would be predicted from linear relationships as the dose increases. For perchloroethylene the opposite holds true. In addition a brief illustration of the use of pharmacokinetic models as tools for interpreting biomarker data is provided.

摘要

不同剂量之间以及不同物种之间会出现药代动力学非线性。基于生理的药代动力学模型是考虑这些非线性的精确工具。二氯甲烷和全氯乙烯是本文讨论的两个例子。对于二氯甲烷,药代动力学非线性因素导致随着剂量增加,实际递送剂量比根据线性关系预测的剂量更大。对于全氯乙烯,情况则相反。此外,还简要说明了药代动力学模型作为解释生物标志物数据工具的用途。

相似文献

1
Physiologically-based pharmacokinetic models in risk and exposure assessment.风险与暴露评估中基于生理学的药代动力学模型
Ann Ist Super Sanita. 1991;27(4):601-8.
2
Species differences in carcinogenicity: the role of metabolism and pharmacokinetics in risk assessment.致癌性中的物种差异:代谢和药代动力学在风险评估中的作用。
Ann Ist Super Sanita. 1991;27(4):595-9.
3
Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.基准剂量和药代动力学模型在非癌症风险评估中的潜在影响研究。
J Toxicol Environ Health. 1997 Dec 26;52(6):475-515. doi: 10.1080/00984109708984077.
4
Comment on M.V. Evans and J.C. Caldwell: evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice, Toxicol. Appl. Pharmacol., 244, 280-290, 2010.对M.V. 埃文斯和J.C. 考德威尔的评论:使用雌性B6C3F1小鼠体内气体摄取数据暴露的生理药代动力学模型对二氯甲烷毒性的两种不同代谢假说进行评估,《毒理学与应用药理学》,244卷,280 - 290页,2010年。
Toxicol Appl Pharmacol. 2010 Oct 1;248(1):63-4; author reply 65-7. doi: 10.1016/j.taap.2010.07.012. Epub 2010 Jul 22.
5
In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans.
Toxicol Appl Pharmacol. 1996 Feb;136(2):289-306. doi: 10.1006/taap.1996.0036.
6
Estimating the risk of human cancer associated with exposure to methylene chloride.评估与接触二氯甲烷相关的人类癌症风险。
Ann Ist Super Sanita. 1991;27(4):609-14.
7
Development and specification of physiologically based pharmacokinetic models for use in risk assessment.用于风险评估的基于生理的药代动力学模型的开发与特性描述。
Regul Toxicol Pharmacol. 2008 Feb;50(1):129-43. doi: 10.1016/j.yrtph.2007.10.012. Epub 2007 Nov 6.
8
Contribution of trichloroacetic acid to liver tumors observed in perchloroethylene (perc)-exposed mice.三氯乙酸对全氯乙烯(Perc)暴露小鼠肝脏肿瘤的影响。
Toxicology. 2009 Jun 16;260(1-3):77-83. doi: 10.1016/j.tox.2009.03.008. Epub 2009 Mar 24.
9
Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans.谷胱甘肽转移酶θ基因多态性对二氯甲烷对人类风险评估的影响。
Toxicol Appl Pharmacol. 1999 Aug 1;158(3):221-30. doi: 10.1006/taap.1999.8715.
10
Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.二氯甲烷癌症风险的修订评估:第一部分 小鼠中的贝叶斯PBPK和剂量反应模型
Regul Toxicol Pharmacol. 2006 Jun;45(1):44-54. doi: 10.1016/j.yrtph.2005.12.007. Epub 2006 Jan 25.

引用本文的文献

1
Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.药代动力学的视角。基于生理的药代动力学建模作为药物研发工具。
J Pharmacokinet Biopharm. 1995 Apr;23(2):217-29. doi: 10.1007/BF02354273.